• In its recently reported second-quarter 2026 results, Abbott Laboratories posted sales of US$12,593 million, up from US$11,142 million a year earlier, while net income fell to US$928 million from US$1,779 million and diluted earnings per share from continuing operations declined to US$0.53 from US$1.01.
• For the first half of 2026, the company grew sales to US$23,757 million from US$21,500 million, but net income and diluted earnings per share from continuing operations dropped to US$2,005 million and US$1.14 respectively, raising questions about cost pressures and profitability even as revenue expands.
• We will now examine how Abbott’s combination of solid revenue growth and weaker earnings reshapes its existing investment narrative.

Rare earth metals are the new gold rush. Find out which 29 stocks are leading the charge.

Abbott Laboratories Investment Narrative Recap

To own Abbott Laboratories, you have to be comfortable with a story built around diversified healthcare revenue and long product cycles, while accepting that earnings can be pressured even when sales rise. The latest quarter reinforces that tension, with solid top line growth but weaker profitability. For now, this mainly sharpens focus on cost control and margin resilience as the key short term catalyst, while litigation and regulatory risks around core products remain a significant overhang.

The most relevant recent announcement is Abbott’s second quarter 2026 earnings release itself, which showed sales growth to US$12,593 million alongside sharply lower net income and diluted EPS. This contrast between revenue momentum and profit compression directly intersects with existing concerns about pricing pressure, cost inflation and legal expenses, and will likely frame how investors weigh the importance of new product launches and emerging market expansion against the risk of sustained margin strain.

But investors should also be aware that rising litigation and regulatory exposure around Abbott’s products could...

Abbott Laboratories’ narrative projects $59.6 billion revenue and $9.5 billion earnings by 2029. This requires 9.7% yearly revenue growth and about a $3.2 billion earnings increase from $6.3 billion today.

Uncover how Abbott Laboratories' forecasts yield a $116.54 fair value, a 16% upside to its current price.

Exploring Other Perspectives

Six Simply Wall St Community fair value estimates for Abbott cluster between about US$116.54 and US$146.06, showing how differently individual investors price the same business. When you set those views against recent revenue growth but weaker earnings, it underlines why you may want to compare several perspectives before deciding how Abbott’s risks and catalysts fit your own expectations.

Explore 6 other fair value estimates on Abbott Laboratories - why the stock might be worth just $116.54!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Abbott Laboratories research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Abbott Laboratories research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Abbott Laboratories' overall financial health at a glance.

Contemplating Other Strategies?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• Find 47 companies with promising cash flow potential yet trading below their fair value.
• Uncover the next big thing with 21 elite penny stocks that balance risk and reward.
• This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.